{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:33:46Z","timestamp":1761093226931,"version":"build-2065373602"},"reference-count":39,"publisher":"Wiley","issue":"8P2","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2724,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:p>Acute coronary syndromes (ACS) consist of unstable angina (UA), non\u2013ST\u2010segment myocardial infarction (NSTEMI) and ST\u2010segment myocardial infarction (STEMI). Timely intervention with effective, predictable antithrombin therapy is critically important in the early management of these conditions. Platelet aggregation is also an important component of thrombus formation in arterial thrombosis. Historically, unfractionated heparin (UFH) has been combined with aspirin to suppress thrombin propagation and fibrin formation; however, its effectiveness has been questioned in this setting. Unlike newer anticoagulant alternatives, UFH paradoxically stimulates platelet aggregation, which may further promote clot formation. In addition, obtaining a valid therapeutic activated partial thromboplastin time (aPTT) in cardiology patients is a major challenge, and dosing is complex. Due to substantial variation in reagents and instruments, target aPTT ranges for UFH in ACS clinical trials cannot be extrapolated to individual institutions. Further, the risk of ischemic events is greater shortly after abrupt discontinuation of UFH compared with alternative agents with longer half\u2010lives and less stimulation of platelet aggregation. Key UA\u2010NSTEMI clinical trials have demonstrated that UFH is inferior to newer agents, such as the low\u2010molecular\u2010weight heparins (LMWHs). Consistent with this evidence, the most recent practice guidelines of the American College of Cardiology and the American Heart Association in UA\u2010NSTEMI identify the LMWH enoxaparin as the agent of choice. In patients with STEMI receiving the fibrinolytic tenecteplase as reperfusion therapy, enoxaparin has also been superior to UFH in combination. In percutaneous procedures, newer indirect (enoxaparin) and direct (bivalirudin) antithrombins have demonstrated safety and efficacy. There is little doubt that as we move forward in optimizing adjunctive anticoagulation in the cardiology setting, UFH will largely be replaced by better antithrombin agents.<\/jats:p>","DOI":"10.1592\/phco.24.12.132s.36110","type":"journal-article","created":{"date-parts":[[2004,7,22]],"date-time":"2004-07-22T10:46:41Z","timestamp":1090493201000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unfractionated Heparin in Cardiology: Redefining the Standard of Practice"],"prefix":"10.1002","volume":"24","author":[{"given":"Thomas L.","family":"Rihn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Heparin Consensus Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00695-1"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610303151801"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.5.870"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-2-199307150-00002"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92336-G"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810273191701"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207163270301"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90407-V"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta analysis","volume":"276","author":"Oler A.","year":"1996","journal-title":"JAMA"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.24.2994"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00487-6"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1593"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1602"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382102"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609123351103"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(19)41499-2"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.4.667"},{"key":"e_1_2_1_21_2","first-page":"212","volume-title":"Textbook of interventional cardiology","author":"Lincoff AM","year":"1993"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.7.961"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo\u2010controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of glycoprotein IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators.","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000050144.67910.13"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00165-0"},{"key":"e_1_2_1_28_2","unstructured":"BlazingMA deLemosJA WhiteHA et al.The A\u2010phase of the Aggrastat to Zocor (A to Z) trial: comparison of the efficacy and safety of unfractionated heparin versus enoxaparin as adjunctive therapy to baseline treatment in individuals who present with non\u2013ST elevation acute coronary syndromes: late\u2010breaking trials.Presented at the 52nd annual scientific session of the American College of Cardiology Chicago IL March 30April 2 2003."},{"key":"e_1_2_1_29_2","unstructured":"MahaffeyK. FergusonJ.Superior yield of the new strategy of enoxaparin revascularization and glycoprotein IIb\/IIIa inhibitors (SYNERGY).Presented at the 53rd annual scientific session of the American College of Cardiology New Orleans LA March 710 2004."},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02336-7"},{"key":"e_1_2_1_31_2","first-page":"II","article-title":"Reduction in major morbidity and mortality by heparin in acute myocardial infarction [abstr]","volume":"78","author":"MacMahon S.","year":"1988","journal-title":"Circulation"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.67.2.122"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91590-7"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91893-D"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89305-8"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00392-0"},{"key":"e_1_2_1_38_2","first-page":"1016","article-title":"ACC\/AHA guidelines for the management of patients with acute myocardial infarction: update","volume":"100","author":"American College of Cardiology, American Heart Association.","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000081659.72985.A8"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.24.12.132S.36110","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.24.12.132S.36110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:43:49Z","timestamp":1761043429000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.24.12.132S.36110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":39,"journal-issue":{"issue":"8P2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1592\/phco.24.12.132S.36110"],"URL":"https:\/\/doi.org\/10.1592\/phco.24.12.132s.36110","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}